Phase 3 TNBC - Triple-Negative Breast Cancer Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 3
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting
Phase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Fudan University424 enrolled2 locationsNCT05999149